Portal de Periódicos da CAPES

A Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human Papillomavirus

2002; Mary Ann Liebert, Inc.; Volume: 13; Issue: 9 Linguagem: Inglês

10.1089/104303402753812520

1557-7422

Carlos Manual Corona Gutierrez, Alberto Tinoco, Mario López Contreras, Tania Navarro, Patricia Calzado, Laura Vargas, Lise Reyes, Roberto Posternak, Ricardo Rosales,

Hepatitis B Virus Studies

Human Gene TherapyVol. 13, No. 9 Clinical ProtocolsA Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human PapillomavirusPublished Online:6 Jul 2004https://doi.org/10.1089/104303402753812520AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byStrategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccinesJournal of Virological Methods, Vol. 251The role of HPV vaccination in the prevention of anal dysplasiaSeminars in Colon and Rectal Surgery, Vol. 28, No. 2Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract31 January 2016 | Clinical Cancer Research, Vol. 22, No. 3Human Papillomavirus VaccineRegression of Human Papillomavirus Intraepithelial Lesions Is Induced by MVA E2 Therapeutic Vaccine Ricardo Rosales, Mario López-Contreras, Carlos Rosales, Jose-Roberto Magallanes-Molina, Roberto Gonzalez-Vergara, Jose Martin Arroyo-Cazarez, Antonio Ricardez-Arenas, Armando del Follo-Valencia, Santiago Padilla-Arriaga, Miriam Veronica Guerrero, Miguel Angel Pirez, Claudia Arellano-Fiore, and Freddy Villarreal30 September 2014 | Human Gene Therapy, Vol. 25, No. 12Human Papillomavirus-Specific Immune Therapy: Failure and Hope1 October 2010 | Antiviral Therapy, Vol. 15, No. 7Prophylaktische und therapeutische Vakzinen gegen humane Papillomviren12 June 2010 | HNO, Vol. 58, No. 8In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate12 May 2009 | Virology Journal, Vol. 6, No. 1Medical treatment of cervical intraepithelial neoplasia II, III: an update review20 February 2009 | International Journal of Clinical Oncology, Vol. 14, No. 1Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeVaccine, Vol. 25, No. 25MVA E2 Recombinant Vaccine in the Treatment of Human Papillomavirus Infection in Men Presenting Intraurethral Flat CondylomaBioDrugs, Vol. 21, No. 1Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine3 February 2006 | Cancer Gene Therapy, Vol. 13, No. 6Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell linesJournal of General Virology, Vol. 87, No. 1Fighting Cancer with Vaccinia Virus: Teaching New Tricks to an Old DogMolecular Therapy, Vol. 11, No. 2Female Genital Tract Infections and Immunity in Animal ModelsModified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?Current Opinion in Biotechnology, Vol. 15, No. 6Therapeutic Vaccination with MVA E2 Can Eliminate Precancerous Lesions (CIN 1, CIN 2, and CIN 3) Associated with Infection by Oncogenic Human Papillomavirus Carlos Manuel Corona Gutierrez, Alberto Tinoco, Tania Navarro, Mario López Contreras, Roberto Risco Cortes, Patricia Calzado, Lise Reyes, Roberto Posternak, Gianni Morosoli, Mauro Lara Verde, and Ricardo Rosales7 July 2004 | Human Gene Therapy, Vol. 15, No. 5 Volume 13Issue 9Jun 2002 To cite this article:A Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human Papillomavirus.Human Gene Therapy.Jun 2002.1127-1140.http://doi.org/10.1089/104303402753812520Published in Volume: 13 Issue 9: July 6, 2004PDF download